MedTrace Logo

Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid

NCT00729924 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-03-03

Study results available
· View outcomes & findings →

Summary

This study is being done to find out how much of the drug raltegravir (RGV) gets into cerebrospinal fluid (CSF), compared to how much get into the blood and to find out if normal changes in a certain gene in your body affects how much RGV gets into the CSF.

Conditions

  • HIV Infections

Interventions

DRUG

Raltegravir

400mg orally every 12 hours for 7 days

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • David W Haas, MD · Vanderbilt University Medical Center

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2011-02-28
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00729924 on ClinicalTrials.gov